Inter-relationships between left ventricular mass, geometry and arterial stiffness

Manal M. Alem\(^1\) and Abdullah M. Alshehri\(^2\)

Abstract

Objective: To investigate the inter-relationships between left ventricular mass (LVM), left ventricular (LV) geometry and arterial stiffness parameters (aortic pulse wave velocity [Ao-PWV] and heart rate-corrected augmentation index [c-AIx]) in patients with chronic heart failure (CHF).

Methods: This study was a secondary analysis of existing data that were collected from patients with CHF New York Heart Association class I–III with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Transthoracic echocardiography was performed on all patients, along with measurement of arterial stiffness parameters (Ao-PWV and c-AIx) using sphygmocardiography.

Results: A total of 73 patients (58 males) with a mean ± SD age of 55.9 ± 11.6 years were enrolled in this study. Of these, 20 patients (27.4%) had systemic hypertension, 46 (63.0%) had type 2 diabetes mellitus. Ischaemic heart disease was the main aetiology of CHF (63 of 73 patients; 86.3%). In multiple linear regression, the left ventricular mass index (LVMI) was significantly associated with c-AIx (\(b = -1.59\)) and EF (\(b = -1.51\)). Comparison of Ao-PWV among the four LV geometric patterns revealed significant differences.

Conclusion: In this cohort of CHF patients, LVMI was predicted by c-AIx and EF. The corresponding values of Ao-PWV were parallel in different LV geometric patterns and confirmed their adverse prognostic values.

\(^1\)Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

\(^2\)Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Corresponding author:
Manal M. Alem, Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, PO Box 1982, Building A76 King Faisal Road, Dammam 31441, Saudi Arabia.
Email: malem@iau.edu.sa
Keywords
Arterial stiffness, aortic pulse wave velocity, augmentation index, chronic heart failure, left ventricular hypertrophy, left ventricular mass index, left ventricular geometry

Date received: 22 June 2019; accepted: 8 January 2020

Introduction
Cardiovascular diseases and their complications are among the main cause of death worldwide.1 The list of recognized cardiovascular risk factors identifies left ventricular hypertrophy (LVH) as an independent risk factor, which was associated with significant cardiovascular morbidity and mortality in the Framingham Heart Study population.2 While defined as an increase in the muscle mass of the left ventricle (LV) and described as a risk factor, LVH appears to be an adaptive process in response to systemic and regional haemodynamic factors and hence can also be described as target organ damage.3 In addition to LV mass (LVM) itself, the geometric pattern of the LV carries its own independent prognostic significance. For example, the Framingham Heart Study demonstrated that subjects with concentric hypertrophy had the worst prognosis, followed by those with eccentric hypertrophy, concentric remodelling and normal geometry.4 Patients with chronic heart failure (CHF) are expected to have an element of LVH, either because of a pre-existing hypertensive heart disease that has become complicated by CHF;5 or because of pre-existing coronary artery disease that predisposes to the development of LVH, even when blood pressure is normal.6

Recently, arterial stiffness (AS) has also been recognized as an independent cardiovascular risk factor, with major prognostic importance particularly attributed to carotid-femoral (aortic) pulse wave velocity (Ao-PWV), more than augmentation index (AIx).7 The Framingham Heart Study reported that a single standard deviation increase in Ao-PWV was associated with a 48% increase in risk for a first major cardiovascular event.8 Increased Ao-PWV in patients with CHF in particular is strongly associated with a poor prognosis.9 In addition to an increased cardiovascular risk, higher Ao-PWV together with a higher LVM plays a role in the development of cognitive impairment in later age in the general population;10,11 a phenomenon that is commonly linked to heart failure.12 The relationship however between arterial stiffness and LVM in patients with CHF has not been specifically studied. Previous studies have shown that AS, in particular the parameter of backward wave pressure, contributes to LVM and LVH.13,14 The present study aimed to observe the interrelationships between LVM, LV geometry and AS parameters in patients with CHF.

Patients and methods
Study design and patient population
This study was a secondary analysis of existing data that were collected from patients with CHF New York Heart Association (NYHA) class I–III with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). These patients had participated in a prospective, randomized, double-blind, placebo-controlled study that assessed the short-term
effect of allopurinol treatment on AS parameters.\textsuperscript{15} This study was conducted at King Fahd Hospital of the University-Al Khobar, Saudi Arabia between February 2011 and August 2013.

Patients aged >18 years with clinically stable, compensated CHF (NYHA functional class I–III) with reduced or preserved ejection fraction (EF) were recruited to the study. Heart failure was defined by the presence of exercise intolerance, along with signs of volume overload (pulmonary congestion, raised jugular venous pressure and peripheral oedema). Reduced systolic function was defined as left ventricular EF <50\%. All patients received optimal anti-heart failure medications and they were on sodium restriction (defined as <3 g/day) and fluid restriction (<1.5 l/day). Clinical stabilization of cardiac status and optimal medications were required for at least 3 months before enrolment. Patients were excluded if they had any of the following: (i) creatinine clearance of <60 ml/min; (ii) admission to hospital within the previous 3 months due to decompensated heart failure or new ischaemic event; (iii) uncontrolled blood pressure (BP) (>160/100 mmHg).

The protocol was approved by the Research Ethics Committee, Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia (no. 201065). Written informed consent was obtained from all patients and the study was conducted in accordance with the Declaration of Helsinki.

**Study procedure**

Transthoracic echocardiography was performed using a Vivid E9 machine (GE Medical Systems, Waukesha, WI, USA) equipped with a 3 MHz transducer. Parasternal and apical 2-dimensional echocardiogram (2D) was also performed.

### Measurement of LVM

The LVM was calculated according to the guidelines of the American Society of Echocardiography and the European Association of Cardiovascular Imaging, using linear measurements derived from 2D images according to the following equation:\textsuperscript{16}

\[
LVM(g) = 0.8 \times \{1.04 \\
\times [(LV \text{ end diastolic dimension} \\
+ \text{Posterior wall thickness at end} \\
- \text{diastole} \\
+ \text{Interventricular septal thickness at end} \\
- \text{diastole})^3 \\
- (LV \text{ end diastolic dimension})^3] \}
+ 0.6 \ g
\]

The LVM was indexed to body surface area (BSA) (g/m\(^2\)) and referred to as the left ventricular mass index (LVMI) because of the strong association between LVM and BSA.\textsuperscript{17} Left ventricular relative wall thickness (RWT) was calculated using the formula (2 x posterior wall thickness)/(LV end-diastolic dimension).\textsuperscript{16} This allows further classification of LV geometry, according to the following criteria:\textsuperscript{16} (i) patients with normal LVM can either have normal geometry (RWT ≤0.42) or concentric remodelling (RWT ≥0.42); (ii) patients with increased LVM can have either concentric hypertrophy (RWT ≥0.42) or eccentric hypertrophy (RWT ≤0.42).

### Measurement of AS parameters

Patients had to report in a fasted state (12 h) within 2 weeks of their echocardiography visit. Water and morning medications were allowed. After 30 min of supine rest, two readings of BP were taken using a CARESCAPE V100 vital signs monitor with Dinamap technology (GE El Seif Alem and Alshehri 3
Healthcare Arabia, Riyadh, Saudi Arabia). Pulse wave analysis (PWA) and pulse wave velocity (PWV) were measured using a SphygmoCor® system (AtCor Medical Pty Ltd., Sydney, Australia). PWA was started by performing eight readings of AIx that were corrected for a heart rate of 75 beats/min (c-AIx). PWA software allows derivation of the corresponding central BP data from the derived central pressure wave for systolic BP (c-SBP), diastolic BP (c-DBP), mean arterial pressure (c-MAP) and pulse pressure (c-PP). The types of arterial pressure waves were characterized into four types: A, B, C and D;18 where AIx was >12%, <0.0% and ≤ 12%, ≤ 0.0% or >12%, respectively (Supplement 1). Furthermore, aortic backward wave pressure and reflection index were determined from the wave separation analysis of the SphygmoCor®-derived aortic waveform. PWV followed by two readings for Ao-PWV (carotid-femoral) and two readings for brachial pulse wave velocity (carotid-radial). Details on the methodology, reporting and interpretation of AS parameters were covered in the original study.15

**Statistical analyses**

All statistical analyses were performed using Minitab statistical software, version 18 (Minitab Inc., State College, PA, USA). Baseline data are presented as mean ± SD for continuous variables and as number and percentages for categorical variables. Median and ranges of values were used for data that were not normally distributed. Comparisons were made using unpaired Student’s t-test for continuous variables or the χ²-test for categorical variables. The Mann–Whitney U-test was used for data that were not normally distributed. Relationships between continuous variables were quantified using Spearman’s rank correlation coefficient. The primary endpoint (i.e. the interaction between AS parameters (Ao-PWV and c-AIx) and LVMI) was tested using multiple regression analysis. One-way analysis of variance and Kruskal–Wallis tests were used for the secondary endpoint (i.e. the comparison of AS parameters among different LV geometry patterns). A P-value <0.05 was considered statistically significant.

**Results**

This study analysed data from 73 patients (58 males, 15 females) with CHF NYHA class I–III. The most common aetiology of CHF was ischaemic heart disease (63 of 73 patients; 86.3%). Of the 73 patients, 20 (27.4%) had a history of systemic hypertension, 46 patients (63.0%) had type 2 diabetes mellitus and six (8.2%) had atrial fibrillation (Table 1). The peripheral BP, AS parameters, LVM, LVMI and biochemical characteristics of the patients are presented in Table 2. The mean ± SD central BP figures for the entire study cohort were as follows (mmHg): c-SBP was 119.3 ± 18.7 (95% confidence interval [CI] 114.9, 123.6); c-DBP was 73.3 ± 11.0 (95% CI 70.7, 75.8); c-MAP was 92.6 ± 12.7 (95% CI 89.6, 95.5); and c-PP was 46.0 ± 15.2 (95% CI 42.5, 49.6). The baseline lipid profile data for the entire study cohort were as follows (median [interquartile range]; mg/dl): total cholesterol 150.0 (94.0–264.0), triglycerides 133.0 (22.0–380.0), high-density lipoprotein cholesterol 37.0 (22.0–70.0) and low-density lipoprotein cholesterol 87.0 (55.0–187.0).

The patient population was then subdivided into two groups based on the presence or absence of LVH according to a normal range of 49–115 g/m² for males and 43–95 g/m² for females.16 Accordingly, 20 patients (27.4%) were found to have LVH (five of them had underlying hypertension and two had hypertensive heart disease as an aetiology of CHF); while the remaining 53 did not have LVH (Table 1). Significantly higher values of LVM and LVMI were observed in patients with LVH compared with those
Table 1. Baseline clinical and demographic characteristics of the entire study cohort (n = 73) and the patients with chronic heart failure (CHF) stratified according to the absence or presence of left ventricular hypertrophy (LVH) and whether they had reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

| Characteristic                      | All patients | Patients without LVH | Patients with LVH | Statistical analysis | Patients with HFrEF | Patients with HFpEF | Statistical analysis |
|-------------------------------------|--------------|----------------------|-------------------|----------------------|--------------------|--------------------|----------------------|
|                                     | n = 73       | n = 53               | n = 20            |                      | n = 47             | n = 26             |                      |
| Age, years                          | 55.9 ± 11.6  | 54.3 ± 11.7          | 60.3 ± 10.3       | P = 0.038            | 56.1 ± 11.9        | 55.7 ± 11.3        | NS                   |
| Sex, males                          | 58 (79.5%)   | 45 (84.9%)           | 13 (65.0%)        | NS                   | 38 (80.9%)         | 20 (76.9%)         | NS                   |
| Height, cm                          | 163.6 ± 10.6 | 164.9 ± 10.2         | 160.2 ± 11.3      | NS                   | 163.6 ± 10.6       | 163.6 ± 10.9       | NS                   |
| Weight, kg                          | 77.7 ± 17.0  | 79.1 ± 17.5          | 74.0 ± 15.5       | NS                   | 76.3 ± 16.7        | 80.4 ± 17.6        | NS                   |
| BMI, kg/m²                          | 29.0 ± 5.3   | 29.0 ± 5.30          | 28.9 ± 5.5        | NS                   | 28.4 ± 5.4         | 29.9 ± 5.2         | NS                   |
| Aetiology of CHF                    |              |                      |                   |                      |                    |                    |                      |
| Ischaemic heart disease             | 63 (86.3%)   | 45 (84.9%)           | 18 (90.0%)        |                      | 42 (89.4%)         | 21 (80.8%)         | NS                   |
| Non-ischaemic heart disease         | 6 (8.2%)/2 (2.7%)/ (HHD/DCM/ valvular/ DM-related CM) | 4 (7.5%)/2 (3.8%)/ 1 (1.4%)/1 (1.4%)/ 1 (1.9%)/1 (1.9%)/ | 2 (10.0%)/0/0/0/0 – |                      | 3 (6.4%)/1 (2.1%)/ | 3 (11.5%)/1 (3.8%)/ | –                   |
| Hypertension                        | 20 (27.4%)   | 15 (28.3%)           | 5 (25.0%)         | NS                   | 15 (31.9%)         | 5 (19.2%)          | NS                   |
| Type 2 diabetes mellitus            | 46 (63.0%)   | 30 (56.6%)           | 16 (80.0%)        | NS                   | 33 (70.2%)         | 13 (50.0%)         | NS                   |
| Atrial fibrillation (paroxysmal and permanent) | 6 (8.2%) | 5 (9.4%) | 1 (5.0%) | NS | 4 (8.5%) | 2 (7.7%) | NS |
| NYHA class                          |              |                      |                   |                      |                    |                    |                      |
| 1                                   | 6 (8.2%)     | 6 (11.3%)            | 0 (0.0%)          |                      | 4 (8.5%)           | 2 (7.7%)           | NS                   |
| 2                                   | 57 (78.1%)   | 42 (79.2%)           | 15 (75.0%)        |                      | 35 (74.5%)         | 22 (48.4%)         | NS                   |
| 3                                   | 10 (13.7%)   | 5 (9.4%)             | 5 (25.0%)         |                      | 8 (17.0%)          | 2 (7.7%)           | NS                   |
| Ejection fraction                   | 43.0 (32.5, 55.0) | 45.0 (35.0, 55.0) | 29.0 (20.0, 35.8) | P ≤ 0.001            | 35.0 (28.0, 43.0) | 57.5 (51.8, 60.0) | P ≤ 0.001            |
| Fractional shortening, %           | 23.7 (17.0, 35.0) | 25.0 (9.3, 49.8) | 17.35 (6.6, 37.1) | P = 0.003            | 19.0 (15.0, 23.4) | 36.5 (32.6, 42.1) | P ≤ 0.001            |
| Diastolic dysfunction               |               |                      |                   |                      |                    |                    |                      |
| Not reportedb                        | 7 (9.6%)     | 6 (11.3%)            | 1 (5.0%)          |                      | 0 (0.0%)           | 7 (26.9%)          | NS                   |
| Grade 1 (delayed relaxation)        | 47 (64.4%)   | 36 (67.9%)           | 11 (55.0%)        |                      | 30 (63.8%)         | 17 (65.4%)         | NS                   |
| Grade 2 (pseudonormal filling)      | 19 (26.0%)   | 11 (20.8%)           | 8 (40.0%)         |                      | 17 (36.2%)         | 2 (7.7%)           | NS                   |
| History of smoking                  |               |                      |                   |                      |                    |                    | NS                   |
| Active/ex-smoker                    | 35 (47.9%)   | 26 (49.1%)           | 9 (45.0%)         |                      | 22 (46.8%)         | 13 (50.0%)         | NS                   |
| Never                               | 38 (52.1%)   | 27 (50.9%)           | 11 (55%)          |                      | 25 (53.2%)         | 13 (50.0%)         | NS                   |
| Cardiac & other medications         |               |                      |                   |                      |                    |                    |                      |
| ACEIs/ARBs                          | 37 (50.7%)/ 26 (49.1%)/ | 11 (55.0%)/ | NS/NS | 28 (59.6%)/ | 9 (34.6%)/ | P = 0.041/NS |                      |
|                                     | 25 (34.2%)   | 16 (30.2%)           | 9 (45.0%)         |                      | 14 (29.8%)         | 11 (42.3%)         |                      |

(continued)
Table 1. Continued.

| Characteristic              | All patients | Patients without LVH | Patients with LVH | Statistical analysis<sup>a</sup> | Patients with HFrEF | Patients with HFpEF | Statistical analysis<sup>a</sup> |
|-----------------------------|--------------|----------------------|-------------------|----------------------------------|---------------------|---------------------|----------------------------------|
|                             | n = 73       | n = 53               | n = 20            |                                  | n = 47              | n = 26               |                                  |
| Beta blockers/CCBs          |              |                      |                   |                                  |                     |                     |                                  |
|                            |              |                      |                   |                                  |                     |                     |                                  |
|                            | 67 (91.8%)/  | 49 (92.5%)/          | 18 (90.0%)/       | NS/NS                            | 42 (89.4%)/         | 25 (96.2%)/          | NS/NS                            |
|                            | 15 (20.5%)   | 9 (17.0%)            | 6 (30.0%)         |                                  | 7 (14.9%)           | 8 (30.8%)            |                                  |
| Aspirin/clopidogrel         |              |                      |                   |                                  |                     |                     |                                  |
|                            | 66 (90.4%)/  | 48 (90.6%)/          | 18 (90.0%)/       | NS/NS                            | 43 (91.5%)/         | 23 (88.5%)/          | NS/NS                            |
|                            | 36 (49.3%)   | 28 (52.8%)           | 8 (40.0%)         |                                  | 21 (44.7%)          | 15 (57.7%)           |                                  |
| Warfarin                   |              |                      |                   |                                  |                     |                     |                                  |
|                            | 6 (8.2%)     | 5 (9.4%)             | 1 (5.0%)          | NS                              | 4 (8.5%)            | 2 (7.7%)             | NS                              |
| Thiazide/loop diuretics    |              |                      |                   |                                  |                     |                     |                                  |
|                            | 12 (16.4%)/  | 9 (17.0%)/           | 3 (15.0%)/        | NS/P = 0.014                     | 3 (6.4%)/           | 9 (34.6%)/           | P = 0.002/NS                    |
|                            | 34 (46.6%)   | 20 (37.7%)           | 14 (70.0%)        |                                  | 25 (53.2%)          | 9 (34.6%)            |                                  |
| Spironolactone             |              |                      |                   |                                  |                     |                     |                                  |
|                            | 24 (32.9%)   | 14 (26.4%)           | 10 (50.0%)        | NS                              | 22 (46.8%)          | 2 (7.7%)             | P = 0.001                      |
| Digoxin                    |              |                      |                   |                                  |                     |                     |                                  |
|                            | 3 (4.1%)     | 2 (3.8%)             | 1 (5.0%)          |                                 | 2 (4.3%)            | 1 (3.8%)             | NS                              |
| Nitroglycerine             |              |                      |                   |                                  |                     |                     |                                  |
|                            | 23 (31.5%)   | 17 (32.1%)           | 6 (30.0%)         | NS                              | 13 (27.7%)          | 10 (38.5%)           | NS                              |
| Oral hypoglycaemic agents/insulin |            |                      |                   |                                  |                     |                     |                                  |
|                            | 34 (46.6%)/  | 23 (43.4%)/          | 11 (55.0%)/       | NS/NS                           | 24 (51.1%)/         | 10 (38.5%)/          | NS/NS                           |
|                            | 14 (19.2%)   | 8 (15.1%)            | 6 (30.0%)         |                                  | 9 (19.1%)           | 5 (19.2%)            |                                  |
| Statins                    |              |                      |                   |                                  |                     |                     |                                  |
|                            | 57 (78.1%)   | 41 (77.4%)           | 16 (80.0%)        | NS                              | 38 (80.9%)          | 19 (73.1%)           | NS                              |

Data presented as mean ± SD or n of patients (%). Median (interquartile range) used for data that were not normally distributed.

<sup>a</sup>Comparisons were made using unpaired Student's t-test for continuous variables or $\chi^2$-test for categorical variables; Mann–Whitney U-test was used for data that were not normally distributed; NS, no significant between-group difference ($P \geq 0.05$).

<sup>b</sup>Seven patients did not have their diastolic function assessed (in six, it was technically difficult; and in one, the patient had permanent atrial fibrillation).

BMI, body mass index; HHD, hypertensive heart disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; CM, cardiomyopathy; NYHA, New York Heart Association; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers.
without ($P \leq 0.001$ for both comparisons) (Table 2). Patients with LVH were associated with less favourable LV geometry patterns ($P \leq 0.001$) and they had significantly higher serum uric acid concentrations ($P=0.010$) compared with the patients without LVH. The patients were subdivided into two groups according to their ejection fraction: 47 patients had HFrEF and 26 patients had HFpEF (Tables 1 and 2). With this classification, patients who had HFpEF had a significantly higher pulse pressure, higher aortic backward wave pressure, along with smaller LVM and LVMI, and a more favourable LV geometry as compared with patients who had HFrEF ($P<0.05$ for all comparisons) (Table 2). Comparing their central BP and lipid profile data based on the presence of LVH or EF, the only significant difference that was observed was a higher c-PP in patients with HFpEF compared with those who had HFrEF (mean ± SD c-PP 51.9 ± 15.1 versus 42.8 ± 14.4 mmHg, respectively; $P=0.016$).

Spearman’s rank correlation coefficient analysis for LVM and LVMI with age, body mass index (BMI), peripheral BP, central BP, EF and AS parameters showed that both LVM and LVMI had an inverse correlation with EF ($P<0.001$ for both comparisons); and a positive correlation with serum creatinine ($P<0.05$ for both comparisons) and serum uric acid (for LVMI only; $P<0.05$) (Table 3). Neither LVM nor LVMI had any significant correlation with BP, either peripheral or central readings. The interaction between SBP and LVMI was plotted separately for those patients with LVH and those without LVH (Figure 1) and in patients with HFpEF and HFrEF (Figure 2). In terms of possible relationships with AS parameters, LVM had a significant inverse correlation with AIx for both the raw and heart rate-corrected values ($P<0.05$ for both comparisons) (Table 3).

A multiple linear regression analysis involving all patients was performed to determine the predictors of LVMI (the outcome, dependent variable). Explanatory or independent variables included in the model were basic demographic factors (age, sex, BMI, SBP, PP), central SBP, central PP, c-AIx, aortic PWV, uric acid, serum creatinine, EF or the presence of underlying hypertension or type 2 diabetes mellitus. For LVMI as the dependent variable, significant predictors were c-AIx ($\beta=-1.59$, $P=0.002$) and EF ($\beta=-1.51$, $P \leq 0.001$). This suggests that patients with higher LVMI were likely to have lower AIx and lower EF. This model explained over 50% of the variability in LVMI, as indicated by R-square (Table 4). The inverse interaction between LVMI and c-AIx was explored further by subdividing the patient group according to sex, age (older or younger than the median age of 56 years) or based on the subtype of their arterial pressure waveform (type A, 55 patients; type B, nine patients; type C, one patient; type D, eight patients). In this subgroup analysis, age and sex continued to show an inverse interaction between LVMI and c-AIx (data not shown), whereas there was a different finding for the different arterial pressure waveforms. In Figure 3, patients with types B and C were analysed as one category (more healthy waveforms), while patients with types A and D were analysed as another category (more pathological waveforms).

Comparison of the Ao-PWV values according to their LV geometric remodelling patterns identified that 32 patients had normal geometry, 14 had concentric remodelling, 20 had eccentric hypertrophy and seven had concentric hypertrophy. There were significant differences in the median Ao-PWV values in the four groups: 8.18, 10.03, 10.50 and 11.15 m/s, respectively ($P=0.019$) (Table 5). A comparison of the reflection index values among the same categories showed an increasing reflection index
Table 2. Baseline haemodynamic, arterial stiffness, left ventricular and biochemical characteristics of the entire study cohort (n = 73) and the patients with chronic heart failure (CHF) stratified according to the absence or presence of left ventricular hypertrophy (LVH) and whether they had reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

| Characteristic                              | All patients | Patients without LVH | Patients with LVH | Statistical analysisa | Patients with HFrEF | Patients with HFpEF | Statistical analysisb |
|---------------------------------------------|--------------|----------------------|-------------------|-----------------------|--------------------|--------------------|-----------------------|
| Systolic blood pressure, mmHg               | 130.1 ± 18.7 | 131.2 ± 17.9         | 127.2 ± 20.8      | NS                    | 127.5 ± 19.2       | 134.9 ± 17.0       | NS                    |
| Diastolic blood pressure, mmHg              | 72.5 ± 10.5  | 72.93 ± 9.95         | 71.2 ± 11.9       | NS                    | 72.9 ± 10.6        | 71.6 ± 10.3        | NS                    |
| Mean arterial pressure, mmHg                | 94.3 ± 12.3  | 95.0 ± 11.8          | 92.6 ± 13.5       | NS                    | 93.8 ± 13.0        | 95.2 ± 11.0        | NS                    |
| Pulse pressure, mmHg                        | 57.2 ± 15.3  | 57.9 ± 14.6          | 55.3 ± 17.2       | NS                    | 53.6 ± 14.5        | 63.7 ± 14.9        | P = 0.007             |
| Heart rate, beats/min                       | 67.0 (600.0, 74.5) | 67.0 (410.0, 95.0) | 67.3 (500.0, 105.0)| NS                    | 67.0 (605.0, 79.5) | 64.8 (57.4, 71.5)  | NS                    |
| Augmentation index, %                       | 28.6 (175.0, 374) | 28.6 (24.0, 45.6)   | 27.8 (–2.5, 43.1) | NS                    | 27.4 (157.0, 375)  | 30.1 (18.9, 37.5)  | NS                    |
| Heart rate-corrected augmentation index, %  | 23.2 ± 10.1  | 23.6 ± 10.4          | 22.1 ± 9.3        | NS                    | 23.8 ± 10.0        | 22.0 ± 10.4        | NS                    |
| Aortic backward wave pressure, mmHg         | 21.9 ± 8.7   | 22.7 ± 8.0           | 21.7 ± 10.7       | NS                    | 19.8 ± 8.0         | 26.0 ± 8.7         | P = 0.006             |
| Reflection index, %                         | 68.0 (519.0, 873) | 66.3 (163.0, 98.7)  | 80.3 (340.0, 972) | NS                    | 68.0 (509.0, 88.9) | 68.7 (535.0, 863.9) | NS                    |
| Aortic pulse wave velocity, m/s             | 9.2 (7.4, 12.5)| 8.8 (5.5, 15.5)     | 10.5 (64.0, 21.7) | NS                    | 9.1 (73.0, 12.7)   | 9.5 (73.0, 12.2)   | NS                    |
| Brachial pulse wave velocity, m/s           | 9.3 ± 1.5    | 9.4 ± 1.4            | 9.0 ± 1.5         | NS                    | 9.5 ± 1.6          | 9.1 ± 1.2          | NS                    |
| Left ventricular mass, g                    | 194.0 (157.0, 239.5)| 177.0 (107.0, 297.0)| 247.0 (159.0, 441.0)| P ≤ 0.001            | 202.0 (161.0, 249.0)| 179.5 (123.5, 220.3)| P = 0.035            |
| Left ventricular mass index, g/m²           | 103.0 (88.5, 125.0)| 96.0 (57.0, 129.0)  | 136.0 (103.0, 238.0)| P ≤ 0.001            | 106.0 (94.0, 135.0)| 95.0 (75.8, 112.8)| P = 0.006            |
| Left ventricular geometry pattern           | Normal geometry | 32 (43.8%)           | 32 (60.4%)       | 0 (0.0%)              | 22 (46.8%)         | 10 (38.5%)         |                        |
|                                            | Concentric remodelling | 14 (19.2%)          | 14 (26.4%)      | 0 (0.0%)              | 4 (8.5%)           | 10 (38.5%)         |                        |
|                                            | Eccentric hypertrophy | 20 (27.4%)          | 4 (7.5%)        | 16 (80.0%)            | 18 (38.3%)         | 2 (7.7%)           |                        |
|                                            | Concentric hypertrophy | 7 (9.6%)            | 3 (5.7%)       | 4 (20.0%)             | 3 (6.4%)           | 4 (15.4%)         |                        |
|                                            | Serum haemoglobin, g/dl | 13.6 ± 1.7         | 13.8 ± 1.7     | 12.8 ± 1.6            | 13.5 ± 1.7         | 13.6 ± 1.9        | NS                    |
|                                            | Uric acid, mg/dl       | 6.2 ± 1.7           | 5.9 ± 1.5      | 7.1 ± 1.9             | 6.1 ± 1.7          | 6.4 ± 1.6        | NS                    |
|                                            | Serum creatinine, mg/dl | 1.0 (0.8, 1.2)    | 1.0 (0.5, 2.5) | 1.1 (0.5, 1.6)      | 1.0 (0.8, 1.2)   | 1.0 (0.9, 1.2)   | NS                    |
|                                            | Serum sodium, meq/ml   | 138.7 ± 3.0         | 138.8 ± 3.1    | 138.4 ± 2.7          | 138.1 ± 3.0        | 139.9 ± 2.7       | P = 0.012            |
|                                            | Fasting blood sugar, mg/dl | 120.0 (100.0, 194.0)| 116.0 (73.0, 442.0)| 141.0 (93.0, 457.0)| 129.0 (104.0, 202.0)| 109.5 (98.0, 171.5)| NS                    |

Data presented as mean ± SD or n of patients (%). Median (interquartile range) used for data that were not normally distributed.

aComparisons were made using unpaired Student's t-test for continuous variables or χ²-test for categorical variables; Mann–Whitney U-test was used for data that were not normally distributed; NS, no significant between-group difference (P ≥ 0.05).

bReadings were based on 69 patients.
for LV subtypes 1 to 4, but this did not reach statistical significance. No significant differences were found when comparing c-AIx and aortic backward wave pressure values among the same categories.

Discussion

Two-dimensional echocardiography remains the most widespread, convenient and standard method for the assessment of LVM, LV geometric remodelling patterns and the detection of LVH. In direct comparison with magnetic resonance imaging, 2D echocardiography provided a reliable performance for LVM assessment and detection of LVH (correlation coefficient of the two imaging modalities, \( r = 0.8, P < 0.001 \)) with limited influence of image quality. Assessments of AS have become more diverse with the derived indices and criteria reflecting different aspects of the

| Characteristic                          | Left ventricular mass, g | Left ventricular mass index, g/m² |
|-----------------------------------------|--------------------------|----------------------------------|
| Age, years                              | -0.029                   | 0.188                            |
| Body mass index, kg/m²                  | 0.304*                   | 0.024                            |
| Ejection fraction, %                    | -0.462**                 | -0.543***                        |
| Fractional shortening, %                | -0.389*                  | -0.409**                         |
| Serum uric acid, mg/dl                  | 0.183                    | 0.279*                           |
| Serum creatinine, mg/dl                 | 0.244*                   | 0.246*                           |
| Augmentation index, %                   | -0.295*                  | -0.083                           |
| Heart rate-corrected augmentation index, % | -0.369*                | -0.169                           |
| Aortic backward wave pressure, mmHg     | -0.144                   | -0.091                           |
| Reflection index, %                     | -0.160                   | 0.053                            |
| Aortic pulse wave velocity, m/s         | -0.034                   | 0.086                            |
| Brachial pulse wave velocity, m/s       | 0.051                    | -0.041                           |

*\(P < 0.05\), **\(P < 0.001\); Spearman’s rank correlation.
Pathophysiology of the arterial tree. Nevertheless, aortic PWV remains the ‘gold standard’ measure of cardiovascular risk.

The interaction between measurements of LVM and AS has been previously studied, but mostly in the context of systemic hypertension.20–22 The findings of the present study were consistent with small scale studies conducted on hypertensive populations and it has shown similar findings with regard to the association between LVM and mid-wall fractional shortening,23,24 serum uric acid, 25,26 and serum creatinine level.27,28 However, the lack of a significant interaction between LVMI and blood pressure (most importantly SBP), as demonstrated in the Framingham Heart Study,29 led to the present study considering the difference in these relationships based on the presence of LVH and underlying EF (Figures 1 and 2). In patients with CHF in the current study, there was a non-significant positive interaction between SBP and LVMI in patients without LVH and in those HFrEF; while, there was a non-significant inverse interaction between SBP and LVMI in patients with LVH and in those HFrEF.

The LVMI was predicted by two factors with inverse interactions, c-AIx and EF, while Ao-PWV was not found to be a significant predictor. The most abundant,
comparable data in the published literature were based on either patients with systemic hypertension or those from community-based studies where the most abundant cardiovascular risk factor was systemic hypertension. For example, a few of these studies failed to show associations between AS indices and LVMI, but several have shown positive interactions between LVMI and Ao-PWV, AIx, backward wave pressure, cardio-ankle vascular index, aortic stiffness and ambulatory arterial stiffness index. Mixed results were reported from patients with chronic kidney disease/haemodialysis and young and healthy adults.

A study consisting of 512 hypertensive patients supported the findings of the present study and showed that AIx correlated inversely with RWT after the age of 65 years, despite the fact that there was a positive correlation for those under 65 years. Such findings were explained by the observation that AIx tends to stabilize or decline after the age of 65 years. Furthermore, an update on 5799 participants from the Framingham Heart Study population (30% were hypertensive) showed that Ao-PWV had a positive association with LVM, while AIx had an inverse association, both of which disappeared when the models were adjusted for mean arterial pressure.

The current findings suggest that there might be an age-related stage where degenerative/pathological processes reverse the expected/physiological relationship between LVMI and c-AIx (Figure 3). In the present study, Ao-PWV was highest in patients with concentric hypertrophy, followed by eccentric hypertrophy, concentric remodeling and lowest in normal geometry. This matches the order of prognostic significance that LV geometry had in the Framingham Heart Study population for total cardiovascular events and all-cause mortality over a follow-up period of 8 years. To the best of our knowledge, this is the first study documenting this association in patients with

![Figure 3. Scatterplot of left ventricular mass index (LVMI) versus heart rate-corrected augmentation index (c-AIx) in patients stratified according to their pulse wave type (type A, 55 patients; type B, nine patients; type C, one patient; type D, eight patients).](image)
In the literature, another study demonstrated a similar relationship for carotid-PWV to show a similar pattern with LV geometry in a population with documented or suspected coronary artery disease.\(^4^6\) While another study showed a similar pattern of worsening Ao-PWV with worsening carotid geometric phenotype in a population-based study, 48% of whom were hypertensive.\(^4^7\)

The main limitations of this current study were the small size of the patient population and the relative lack of statistical power when the subgroups were compared. Comparative interpretation is also compromised because the published literature focuses mainly on patients with systemic hypertension and not cardiac failure. A small study on patients with HFrEF showed AS values similar to this cohort, however their population was a decade older as compared with the present study.\(^4^8\) Also, there was a paucity of information specifically derived from studies in

| Table 5. Comparison of aortic pulse wave velocity (PWV), heart rate-corrected augmentation index (c-AIx), aortic backward wave pressure and reflection index among different left ventricular (LV) geometry patterns for the entire study cohort (n = 73) of patients with chronic heart failure. |
|---------------------------------|-----------------|-----------------|-----------------|
| Aortic PWV                      | Statistical     |                 |
| LV subtype\(^b\)                | Median          | Range           | Statistical     |
|                                 |                 |                 | analysis\(^a\)  |
| 1 (n = 32)                      | 8.18            | 5.50–15.50      | P = 0.019       |
| 2 (n = 14)                      | 10.03           | 6.30–14.20      |                 |
| 3 (n = 19)                      | 10.50           | 6.40–21.65      |                 |
| 4 (n = 7)                       | 11.15           | 8.75–14.65      |                 |
| c-AIx                           |                 |                 |                 |
| LV subtype                      | Mean            | SD              | NS              |
| 1 (n = 32)                      | 22.62           | 11.25           |                 |
| 2 (n = 14)                      | 22.45           | 8.10            |                 |
| 3 (n = 20)                      | 24.05           | 9.21            |                 |
| 4 (n = 7)                       | 24.54           | 12.08           |                 |
| Aortic backward wave pressure   |                 |                 |                 |
| LV subtype\(^b\)                | Mean            | SD              | NS              |
| 1 (n = 30)                      | 20.33           | 7.98            |                 |
| 2 (n = 14)                      | 23.04           | 7.44            |                 |
| 3 (n = 18)                      | 21.34           | 8.82            |                 |
| 4 (n = 7)                       | 28.13           | 12.35           |                 |
| Reflection index                |                 |                 |                 |
| LV subtype\(^b\)                | Median          | Range           | NS              |
| 1 (n = 30)                      | 62.12           | 16.33–96.00     |                 |
| 2 (n = 14)                      | 68.94           | 51.00–98.67     |                 |
| 3 (n = 18)                      | 78.19           | 37.00–97.17     |                 |
| 4 (n = 7)                       | 87.38           | 34.00–90.67     |                 |

Data presented as mean ± SD. Median (interquartile range) used for data that were not normally distributed.

\(^a\)Comparisons were made using one-way analysis of variance and Kruskal–Wallis tests; NS, no significant between-group difference (\(P \geq 0.05\)).

\(^b\)One patient did not have any baseline data for aortic-PWV and four had missing data on aortic backward wave pressure and reflection index.

LV subtypes: 1, normal geometry; 2, concentric remodelling; 3, eccentric hypertrophy; 4, concentric hypertrophy.
the Saudi population with regard to BP, AS, LV structural and functional changes with age, and other risk factors, as well as any superimposed pathological process such as CHF.

In conclusion, this current study was conducted among patients with CHF with different LV geometric patterns. The LVMI was predicted by c-AIx and EF. The lack of a significant association between LVMI and BP was likely due to specific characteristics of this small patient population in terms of LVM and EF. However, these results suggest the need for proper epidemiological studies in the Saudi population. Despite the study limitations, the identification of a correlation between Ao-PWV and LV geometry is entirely consistent with the known adverse prognostic significance in relation to future total cardiovascular events and all-cause mortality established in the literature.

Acknowledgements
The authors are very thankful to all the associated personnel in any reference that contributed in/for the purpose of this research.

Declaration of conflicting interest
The authors declare that there are no conflicts of interest.

Funding
The original prospective, randomized, double-blind, placebo-controlled study from which the data analysed in this current study were derived was funded by the Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia (grant no. 20100065).

ORCID iD
Manal M. Alem https://orcid.org/0000-0001-8447-792X

Supplemental material
Supplemental material for this article is available online.

References
1. Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Rev Cardiol 2018; 15: 106–119.
2. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.
3. Messerli FH and Ketelhut R. Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol 1991; 17: S59–S66.
4. Krumholz HM, Larson M and Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879–884.
5. Gradman AH and Alpayouni F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006; 48: 326–341.
6. Ang DS, Pringle SD and Struthers AD. The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens 2007; 20: 1029–1035.
7. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014; 63: 636–646.
8. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121: 505–511.
9. Bonapace S, Rossi A, Cicoira M, et al. Increased aortic pulse wave velocity as measured by echocardiography is strongly associated with poor prognosis in patients with heart failure. J Am Soc Echocardiogr 2013; 26: 714–720.
10. Scuteri A, Coluccia R, Castello L, et al. Left ventricular mass increase is associated with cognitive decline and dementia in the elderly.
independently of blood pressure. Eur Heart J 2009; 30: 1525–1529.

11. Scuteri A, Tesauro M, Guglini L, et al. Aortic stiffness and hypotension episodes are associated with impaired cognitive function in older subjects with subjective complaints of memory loss. Int J Cardiol 2013; 169: 371–377.

12. Gure TR, Blaum CS, Giordani B, et al. Prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc 2012; 60: 1724–1729.

13. Bello H, Norton GR, Ballim I, et al. Contributions of aortic pulse wave velocity and backward wave pressure to variations in left ventricular mass are independent of each other. J Am Soc Hypertens 2017; 11: 265–274.

14. Sibiya MJ, Norton GR, Booyse HL, et al. Aortic backward waves rather than stiffness account for independent associations between pulse pressure amplification and left ventricular mass in a young to middle-aged sample. J Am Soc Hypertens 2017; 11: 350–358.

15. Alem MM, Alshehri AM, Cahusac PM, et al. Effect of xanthine oxidase inhibition on arterial stiffness in patients with chronic heart failure. Clin Med Insights Cardiol 2018; 12: 1179546818779584.

16. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39.

17. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222–1230.

18. Nichols WW, O’Rourke MF and Vlachopoulos C. Wave reflection. McDonald’s blood flow in arteries. Theoretical, experimental, and clinical principles. 6th ed. CPC Press. Taylor & Francis Group, 2011, pp.195–223.

19. Armstrong AC, Gjesdal O, Almeida A, et al. Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Echocardiography 2014; 31: 12–20.
cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudy. J Am Coll Cardiol 2010; 56: 24–30.
31. Hanis CL, Redline S, Cade BE, et al. Beyond type 2 diabetes, obesity and hypertension: an axis including sleep apnea, left ventricular hypertrophy, endothelial dysfunction, and aortic stiffness among Mexican Americans in Starr County, Texas. Cardiovasc Diabetol 2016; 15: 86.
32. Ohyama Y, Ambale-Venkatesh B, Noda C, et al. Association of aortic stiffness with left ventricular remodeling and reduced left ventricular function measured by magnetic resonance imaging: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging 2016; 9: pii: e004426.
33. Matsui Y, Ishikawa J, Shibasaki S, et al. Association between home arterial stiffness index and target organ damage in hypertension: comparison with pulse wave velocity and augmentation index. Atherosclerosis 2011; 219: 637–642.
34. Sibiya MJ, Norton GR, Hodson B, et al. Gender-specific contribution of aortic augmentation index to variations in left ventricular mass index in a community sample of African ancestry. Hypertens Res 2014; 37: 1021–1027.
35. Masugata H, Senda S, Inukai M, et al. Association between left ventricular hypertrophy and changes in arterial stiffness during hypertensive treatment. Clin Exp Hypertens 2014; 36: 258–262.
36. Ye Z, Pellikka PA and Kullo IJ. Sex differences in associations of cardio-ankle vascular index with left ventricular function and geometry. Vasc Med 2017; 22: 465–472.
37. Bell V, Sigurdsson S, Westenberg JJ, et al. Relations between aortic stiffness and left ventricular structure and function in older participants in the Age, Gene/Environment Susceptibility–Reykjavik Study. Circ Cardiovasc Imaging 2015; 8: e003039.
38. Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47–52.
39. Dellegrottaglie S, Sands RL, Gillespie BW, et al. Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. Nephrol Dial Transplant 2011; 26: 2891–2898.
40. Kim ED, Sozio SM, Estrella MM, et al. Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study. BMC Nephrol 2015; 16: 131.
41. Georgianos PI and Agarwal R. Relative importance of aortic stiffness and volume as predictors of treatment-induced improvement in left ventricular mass index in dialysis. PLoS One 2015; 10: e0135457.
42. Urbina EM, Dolan LM, McCoy CE, et al. Relationship between elevated arterial stiffness and increased left ventricular mass in adolescents and young adults. J Pediatr 2011; 158: 715–721.
43. Wykretowicz M, Katulska K, Milewska A, et al. Left ventricular mass: correlation with fatness, hemodynamics and renal morphology. Pol J Radiol 2014; 79: 426–430.
44. Matsui Y, Ishikawa J, Eguchi K, et al. The influence of wave reflection on left ventricular hypertrophy in hypertensive patients is modified by age and gender. Hypertens Res 2008; 31: 649–656.
45. Kaess BM, Rong J, Larson MG, et al. Relations of central hemodynamics and aortic stiffness with left ventricular structure and function: the Framingham Heart Study. J Am Heart Assoc 2016; 5: e002693.
46. Salvetti M, Paini A, Facchetti R, et al. Relationship between vascular damage and left ventricular concentric geometry in patients undergoing coronary angiography: a multicenter prospective study. J Hypertens 2019; 37: 1183–1190.
47. Scuteri A, Chen CH, Yin FC, et al. Functional correlates of central arterial geometric phenotypes. Hypertension 2001; 38: 1471–1475.
48. Gronda E, Brambilla G, Seravalle G, et al. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. Clin Res Cardiol 2016; 105: 838–846.